Expansive applications of ologen™ Collagen Matrix in eye tissue repair and grafting widely discussed at 2012 EGS

Expansive applications of ologen™ Collagen Matrix in eye tissue repair and grafting widely discussed at 2012 EGS

At the 10th European Glaucoma Society Congress in Copenhagen (June 17 – 22, 2012 ), Prof. T.S. Dietlein (Germany) and Dr. Hans J. Schuitmaker (The Netherlands) called for the need of ready-to-use anti-fibrotics and tissue repair grafting in ophthalmic surgery. Both highlighted ologen™ Collagen Matrix’s comprehensive tissue repair applications in meeting the demand. An overview of the features of the ologen™ Collagen Matrix was presented by Dr. Hans J. Schuitmaker:

Overview of ologen™ Collagen Matrix

– Dr. Hans J Schuitmaker (AAE, Leiden, The Netherlands)

ologen™ Collagen Matrix can be stored at room temperature, is ready-to-use without needing prior preparation, possesses good pliable strength for manipulation and suturing, is not chemo toxic and is completely bio compatible. These features make ologen™ Collagen Matrix a potential alternative and better solution to the homografts and allografts commonly used in the surgery of bleb revision, tube revision (Rosentreter et al. 2010) and repair of scleral thinning. Also, a variety of oculoplastic indications may be envisaged such as those for scleral patches and tutopatch, for corneal lamellar and dermis grafting together with overlying conjunctival mobilization or free grafts (cited from Sangwan V.S., et al. 2007). ologen™ Collagen Matrix’s natural atelocollagen composition, its non-chemo toxicity free of hazard handling also differentiates it from chemo toxic adjuvants such as Mitomycin-C (MMC) and 5-Fluorouracil (5-FU) in ophthalmic anti-fibrosis management.

Following the introduction on the features of ologen™ Collagen Matrix, Prof.dr. T.S. Dietlein proceeded with a presentation on the use of ologen™ Collagen Matrix’s during tube revision and ophthalmic tissue repair. Tube exposure incurring tube revision surgery accounts for a cumulative incidence probability as high as 20.4% six years after glaucoma drainage device (GDD) surgery (Stein et al. 2008). Therefore, tube exposure is a clinically relevant and important issue in glaucoma surgery and in its postoperative management. The incidence may be lowered in the first place by implementing ologen™ Collagen Matrix with GDD, such as to cover the tube of the Ahmed Valve, non-valved Baerveldt or Molteno implants to prevent erosion. ologen™ Collagen Matrix may also be used in conjunction with the EX-PRESS shunt, in canaloplasty to reduce fibrosis, or with antimetabolites in the difficult and previously failed cases. Furthermore, ologen™ greatly enhances the prognosis of bleb and tube revision surgery when encapsulation or erosion have already occurred. The presentation video will be available in the near future when the result is published.

ologen™ for surgical treatment of exposed tubes after GDD surgery
– Prof. Thomas Dietlein (Dept. Ophthalmology, Köln university, Germany)

(Prof. T.S. Dietlein: above) Slide’s content retreived from Rosentreter et al. 2012

(From left to right: Mr. Andy, Dr. J.J. Schuitmaker, Prof. T.S. Dietlein, Dr. K. Daniel, Mr. Arslan)


Rosentreter A, Schild AM, Dinslage S, Dietlein TS. (2012) Biodegradable implant for tissue repair after glaucoma drainage device surgery. J Glaucoma 2012 Feb; 21(2):76-8

Rosentreter A, Mellein AC, Konen WW, Dietlein TS. (2010) Capsule excision and Ologen implantation for revision after glaucoma drainage device surgery. Graefes Arch Clin Exp Ophthalmol 2010 Sep; 248(9): 1319-24. Epub 2010 Apr 20

Sangwan VS, Jain V, Gupta P. (2007) Structural and functional outcome of scleral patch graft. Eye 2007; 21: 930–935; doi:10.1038/sj.eye.6702344

Stein JD, RuizD Jr, Belsky D, Lee PP, Sloan FA. (2008) Longitudinal rates of postoperative adverse outcomes after glaucoma surgery among medicare beneficiaries 1994 to 2005. Ophthalmology 2008; 115: 1109 – 1116